DoP asks NPPA to review, verify Bharat Serum and Vaccine's
The Department of Pharmaceuticals (DoP) has issued an order disposing the review application of Bharat Serum and Vaccine (BSVL) to the National Pharmaceutical Pricing Authority (NPPA) instructing to verify the applicability of GST factor by cross-checking the documents submitted by BSVL pertaining to the formulation Human Normal Immunoglobulin.
DoP asks NPPA to review, verify Bharat Serum and Vaccine’s
The Department of Pharmaceuticals (DoP) has issued an order disposing the review application of Bharat Serum and Vaccine (BSVL) to the Na Products Suppliers
DoP asks NPPA to review prices fixed for Eli Lilly’s insulin
However, the NPPA asked the company to stick to the insulin ceiling price it had fixed earlier, after the review of the case. Eli Lilly has challenged fixing the prices in respect of five different imported formulations of injection Insulin Lispro (Humalog) through an order dated July 19, 2012.
DoP clarifies on NPPA’s price-capping powers, under PMO
The Department of Pharmaceuticals (DoP), under the supervision of the Prime Minister’s Office (PMO), has clarified on certain issues related to price-capping powers of National Pharmaceutical Pricing Authority (NPPA).
Challenges with Fixing the Ceiling Price Under the 2013 DPCO
The Department of Pharmaceuticals (DoP) has directed the NPPA to adopt the correct methodology in all such cases of calculating the ceiling price of scheduled formulations like ciprofloxacin 500 mg and ciprofloxacin 250 mg tablets as per para 4 (i) of DPCO, 2013 and provisions of existing Schedule-I by including market shares of only
